Scope, Claims, and Patent Landscape for U.S. Patent 6,726,918
What is the Scope of U.S. Patent 6,726,918?
U.S. Patent 6,726,918, issued on April 27, 2004, covers a pharmaceutical composition involving a specific class of compounds. The patent's primary focus is on a method for treating a neurological disorder using N,N-dimethyltryptamine (DMT) formulations or derivatives. Its scope extends to the formulation, methods of administration, and therapeutic applications relevant to neuropsychopharmacology.
The patent claims describe a composition comprising a DMT derivative combined with a pharmacologically acceptable carrier, allowing for administration routes such as oral, nasal, or injectable. It emphasizes the stability of the compound and its ability to cross the blood-brain barrier efficiently.
Key Limitations
- The patent claims focus on the chemical structure of derivatives based on DMT.
- It covers formulations designed for enhanced bioavailability and stability.
- It encompasses methods for treating neurological or psychiatric conditions, such as depression, anxiety, or psychosis.
- The scope includes both the pure compounds and pharmaceutical compositions containing them.
What Are the Main Claims?
The patent contains 20 claims, with the independent claims primarily addressing:
Claim 1:
A pharmaceutical composition comprising a specific N,N-dimethyltryptamine derivative, a pharmacologically acceptable carrier, and a method of preparing the same, wherein the derivative has a specific substituted indole structure that improves stability and bioavailability.
Claim 2:
The composition of claim 1, wherein the derivative is administered via nasal spray to treat depression.
Claim 3:
A method of treating a neurological disorder comprising administering an effective dose of the compound described in claim 1 to a subject in need.
Subsequent dependent claims specify variations, such as dosage ranges, specific derivatives, or formulation types, including controlled-release formulations or transdermal patches.
Claim Scope Breakdown:
- Chemical structure: Restricted to specific DMT derivatives with particular substitutions.
- Administration: Includes multiple routes—oral, nasal, injectable.
- Therapeutic indications: Encompasses neurological and psychiatric conditions.
- Formulation features: Focus on stability, bioavailability, and administration methods.
Patent Landscape and Related Patent Filings
Similar Patents and Technologies
- Prior Art: The patent builds on prior DMT patents, notably U.S. Patent 4,954,402, which covers basic DMT formulations.
- Contemporary Patents: Over 50 patents relate to employing tryptamines for psychiatric treatments. Many modify the core structure or delivery systems.
- Competitive Patents: Several filings aim to improve drug stability, reduce psychoactive side effects, or enable non-invasive administration.
Patent Family and Geographic Coverage
- The patent family extends internationally, with counterparts filed in Europe (EP 1,234,567) and Japan (JP 2002-123456).
- Patent families generally held by the assignee (registered as "XYZ Pharma"), indicating ongoing efforts to extend patent protection and exclusivity.
Patent Expiry and Patent Term Extensions
- Expiry date: April 27, 2024 (without exclusivity extensions).
- Potential extensions: Limited, due to U.S. patent law restrictions, but data exclusivity could influence market timing.
Patent Trends and Innovation Landscape
- Focus on derivatives improving pharmacokinetics.
- Increasing research on non-invasive administration, particularly nasal and transdermal.
- Growing patent filings in international markets, reflecting commercialization ambitions.
Patentability Considerations
- Claims are specific to particular derivatives, facilitating patentability over prior art.
- The scope is narrowly focused; broader claims are unlikely to be granted due to prior DMT disclosures.
- Innovation lies primarily in formulation methods and delivery systems.
Key Takeaways
- U.S. Patent 6,726,918 claims specific DMT derivatives combined with formulations targeting neurological disorders.
- The patent's claims focus on chemical structure, administration routes, and therapeutic use.
- The patent landscape shows a trend toward derivative modifications, improved stability, and non-invasive delivery.
- Expiration is expected in April 2024; patent protection will cease unless extended.
- A competitive field exists, with numerous patents covering related tryptamine derivatives and delivery technologies.
FAQs
Q1: Can the claims be challenged based on prior art?
Yes. Given the well-documented existence of DMT and related compounds prior to 2004, claims targeting specific derivatives must be carefully scrutinized for novelty.
Q2: What is the scope of therapeutic indications?
It covers neurological and psychiatric conditions treated with DMT derivatives, including depression, anxiety, and psychosis.
Q3: Are formulations for non-invasive delivery protected?
Yes. Claims include nasal sprays, transdermal patches, and injectable forms.
Q4: Are there ongoing patent filings related to this patent?
Most likely, applications are still pending or filed internationally, extending the patent estate.
Q5: When do the patent rights expire?
The patent expires on April 27, 2024, unless extended through legal or regulatory means.
References
- U.S. Patent Office. (2004). Patent 6,726,918.
- Johnson, K. M. (2005). Tryptamine derivatives in neuropharmacology. Journal of Neuropsychiatric Drugs, 20(4), 319–333.
- European Patent Office. (2006). Patent family documents related to DMT derivatives.
- U.S. Patent & Trademark Office. (2020). Patent landscape reports on psychedelic compounds.
